摘要
目的:探讨多西他赛与顺铂协同应用治疗晚期非小细胞肺癌(NSCLC)的有效性和安全性,为临床治疗提供理论依据。方法:网络检索Cochrane图书馆、EMBase、PubMed、CBM、CNKI等数据库,搜索多西他赛与顺铂协同应用治疗晚期NSCLC的RCTs,时间均从创建至2019年9月。由2名研究员对所得RCTs资料整合、核对,采用RevMan5.2的软件分析。结果:本文共选入14篇RCTs,(1199例患者),其中治疗组611例,对照组588例。研究表明,有效性方面,对照组相比,多西他赛与顺铂组总有效率和临床获益率有显著性差异,总有效率RR(95%CI)为1.56(1.36,1.80);临床获益率RR(95%CI)为1.13(1.07,1.19);安全性方面,治疗组不良反应发生危险度显著低于对照组,白细胞降低、血小板减少、恶心呕吐及脱发方面均低于对照组,RR(95﹪CI)分别为0.69(0.57,0.83)、0.44(0.29,0.65)、0.54(0.40,0.73)、0.49(0.33,0.72)。结论:基于所选证据,在治疗晚期NSCLC方面,治疗组较对照组药物优秀。
Objective:To explore the efficacy and safety of docetaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer(NSCLC),and to provide theoretical basis for clinical treatment.Methods:The databases such as Cochrane Library,EMBASE,PubMed,CBM,CNKI,etc.were searched on the Internet.The RCTs of docetaxel and cisplatin in the treatment of advanced NSCLC were searched from the establishment to September 2019.The data of RCTs were integrated and checked by two researchers and analyzed by Revman 5.2 software.Results:In this paper,14 RCTs(1199 patients)were selected,including 611 in the treatment group and 588 in the control group.In terms of effectiveness,the total effective rate and clinical benefit rate of docetaxel and cisplatin group were significantly different,the total effective rate RR(95%CI)was 1.56(1.36,1.80);the clinical benefit rate RR(95%CI)was 1.13(1.07,1.19);in terms of safety,the risk of adverse reactions in the treatment group was significantly lower than that in the control group,with leukopenia and thrombocytopenia RR(95%CI)was 0.69(0.57,0.83),0.44(0.29,0.65),0.54(0.40,0.73),0.49(0.33,0.72),respectively.Conclusion:Based on the selected evidence,the treatment group was superior to the control group in the treatment of advanced NSCLC.
作者
耿帅
郭宏举
GENG Shuai;GUO Hongju(Strategic Support Force Characteristic Medical Center, Beijing 100101, China)
出处
《河北医学》
CAS
2020年第4期620-625,共6页
Hebei Medicine
基金
战略支援部队特色医学中心医药卫生基础研究探索课题,(编号:19ZX63)
战略支援部队特色医学中心军事医学研究课题,(编号:19ZX17)。
